Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies - ALARM3

NCT05772559 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT05772559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05772559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies - ALARM3
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Overall status
Recruiting
Start date
May 31, 2023
Completion date
May 31, 2033
Enrollment
500 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, genetic predisposition to disease